Chronic nitric oxide synthase inhibition prevents new coronary capillary generation

Daphné Girardot1, Bernard Jover, Jean-Pierre Moles

  • 1Faculty of Pharmacy, Université de Montréal, Montréal, Canada.

Insights

Nitric oxide synthase inhibition with L-NAME reduces coronary capillary growth, leading to concentric cardiac remodeling in hypertension. This suggests limiting new capillary formation prevents ventricular hypertrophy.

Area of Science:

  • Cardiovascular Physiology
  • Vascular Biology
  • Nitric Oxide Signaling

Background:

  • L-NAME-induced hypertension causes concentric cardiac remodeling despite increased afterload.
  • The role of nitric oxide synthase inhibition in limiting coronary capillary growth remains unclear.

Purpose of the Study:

  • To investigate the impact of endogenous and exogenous nitric oxide on coronary neovascularization.
  • To determine if nitric oxide synthase inhibition affects coronary capillary growth and cardiac remodeling.

Main Methods:

  • In vitro incubation of aortic and coronary rings with L-NAME or nitric oxide donor SNAP in a collagen matrix.
  • Assessment of neovascularization in arterial rings from rats chronically treated with L-NAME.
  • Evaluation of capillary density in the myocardium of L-NAME-treated rats.

Main Results:

  • L-NAME inhibited, while SNAP stimulated, in vitro neovascularization of aortic and coronary rings.
  • Chronic L-NAME treatment reduced capillary generation in coronary rings.
  • L-NAME-treated rats exhibited concentric cardiac remodeling without altered myocardial capillary density.

Conclusions:

  • Chronic inhibition of nitric oxide synthesis in vivo impairs coronary artery neovascularization capacity.
  • Reduced capillary formation may prevent compensatory ventricular hypertrophy, favoring concentric remodeling.

Related Concept Videos

Nitric Oxide Signaling Pathway01:28

Nitric Oxide Signaling Pathway

Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure to...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...